RevBio was awarded a two-year, $2 million Phase II Small Business Innovation Research to pursue the treatment of wrist fractures with its Tetranite® bone adhesive technology. The injectable adhesive requires only a small incision to deliver the material, making it a more minimally invasive treatment option than standard open surgery.
Other applications in various stages of development for the technology include spinal fusion, joint reconstruction, suture anchor attachment, animal health, etc.
"This opportunity really showcases the reason we invented this product—to provide surgeons with a first ever regenerative bone adhesive," said Brian Hess, CEO of RevBio. "This is the first of many indications we intend to launch to revolutionize how bone fractures are treated."